# **Special Issue**

# **Lung Injury and Repair**

## Message from the Guest Editor

We are pleased to announce the launch of the "Lung" Injury and Repair "Special Issue of Pharmaceuticals. This Special Issue will emphasize the most recent advances in the field of pulmonary biology and therapeutics, to provide the research and medical community with the most up-to-date information in the corresponding fields. We welcome the submission of manuscripts (research articles, reviews) investigating the etiologies of lung disease, as well as the development of medical countermeasures against lung injury (direct and indirect). Such injuries include (but are not limited to) the following: acute lung injury, acute respiratory distress syndrome, aspiration, sepsis. trauma, SARS-CoV-2-inflicted ARDS, pneumonia, fibrosis, lung endothelial, and epithelial cell injury. The further delineation of the signaling network that maintains states of lung health and disease will propel the discovery of highly targeted and efficacious approaches against the ferocious outcomes of respiratory dysfunction, including COVID-19.

## **Guest Editor**

Dr. Nektarios Barabutis

College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA

## Deadline for manuscript submissions

closed (31 January 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/60888

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

